Study Design. Systematic review. Objective. To evaluate the current biomechanical and clinical evidence available on the use and effectiveness of lumbar interspinous devices and to recommend indications for their use.
Several interspinous spacers (ISPs) are currently available in the market. Though they vary in design and composition, their common mechanical goal is distraction between adjacent spinous processes and thus blocking intervertebral extension at that level. There has been several proposed indication for their use including lumbar canal stenosis, Grade 1 degenerative spondylolisthesis, discogenic low back pain, nontraumatic instability, lumbar disc herniation, and facet syndrome. [1] [2] [3] [4] However, proper evidence for such widespread use is currently lacking. The main aim of this paper is to critically analyze the current biomechanical and clinical evidence available about ISPs.
Materials and Methods

Inclusion Criteria
Population of interest: Adult patients with degenerative disease of the lumbar spine.
Types of studies included: Clinical and biomechanical studies including cadaveric studies.
Types of interventions: Treatment of degenerative disease of the lumbar spine by insertion of interspinous spacers.
Types of outcome measures: For the clinical studies, outcome assessment was based on patient-related outcome measures with regards to pain and quality of life using various validated questionnaires, e.g., Oswestry disability index (ODI), Zurich claudication questionnaire (ZCQ), Short Form 36 (SF-36), SSSQ (Swiss spinal stenosis questionnaire), etc. For the biomechanical studies, the main outcome measure was to see if insertion of ISPs significantly affected the kinematics of the lumbar spine and spinal canal and neural foramens diameter (with or without concomitant decompression).
Exclusion Criteria
Articles describing novel techniques, nonconventional techniques e.g., endoscopic decompression and case reports were excluded. A minimum follow-up of 1 year was needed for clinical studies.
Search Strategy
Relevant biomechanical and clinical studies meeting the above criteria were identified as follows:
and Allied Health Literature), and PubMed was performed. 2. The following keywords were used: interspinous implants, interspinous devices, dynamic stabilization, interspinous spacer, X-STOP, Coflex, Wallis, DIAM. 3. For the selected articles, the reference list was also reviewed.
Method of Review
The abstracts were initially reviewed to ensure that there were no exclusion criteria. If no clear exclusion criteria were identified, the full journal article was subsequently obtained. The biomechanical and clinical papers were analyzed. The following effects of the ISPs were specifically noted when analyzing the biomechanical papers: stability at instrumented level, distraction, spinal canal and neural foramen dimension, intradiscal pressure, effect on facet joints, adjacent level degeneration/ instability, and concomitant lumbar surgery. The methodology of the clinical papers was also reviewed.
Results
The relevant biomechanical and clinical articles are outlined in Tables 1-4 . The relevant features of the currently available spacers are outlined in Table 5 . Let us briefly discuss the relevant articles regarding each type of spacer.
X-STOP
Biomechanical Studies A total of 10 studies were found, which reported the effect of X-STOP on the kinematics of the lumbar spine. [5] [6] [7] [8] [9] [10] [11] [12] 38 Six were cadaveric studies. Analysis of the studies shows that X-STOP has some beneficial effects on the kinematics of the spine. The important biomechanical findings of the studies are as follows: (1) decrease in flexion-extension range of movement at instrumented level; (2) significant increase in neural foramen and spinal canal dimension; (3) decrease in intradiscal pressure at instrumented level in neutral and extended position; (4) decrease in mean peak pressures, average pressures, contact area and force at the facets; (5) no significant alteration of kinematics or accelerated disc degeneration at adjacent levels; (6) no significant change in intervertebral angle, posterior disc height, and interspinous process distance.
The clinical as well as the laboratory studies available on the X-STOP have mainly focused on its use as a "stand-alone" device. In a cadaveric study by Fuchs et al, 8 X-STOP was additionally evaluated in combination with graded facetectomies. Their study suggested that the implant may be used in conjunction with a unilateral medial facetectomy or unilateral total facetectomy but not with a bilateral total facetectomy. However, it is worth noting that use of X-STOP with concomitant lumbar surgery is not one of the indications advocated by the developer.
Clinical Evidence
There have been 2 prospective randomized controlled trials with the X-STOP device. Zucherman et al were the first to publish results of a prospective, comparative, multicenter, randomized trial, in which 100 patients were treated with the X-STOP and 91 patients received nonoperative management. 10, 28, 31 Patients had to be at least 50 years old and have leg, buttock, or groin pain with or without back pain that was relieved during flexion. Eligible patients had to be able to sit for 50 minutes without pain, walk 50 feet or more, and have completed at least 6 months of nonoperative therapy. Stenosis was confirmed by CT or MRI scans at 1 or 2 levels. Results at 1 year were analyzed using the ZCQ and the SF-36.
However, only the ZCQ was used for the 2-year followup. They observed a significantly greater improvement in clinical symptoms in the X-STOP group compared with controls (nonoperative) at all time points. At 2 years, 60.2% patients reported a clinically significant improvement in the Symptom Severity domain and 57% reported clinically significant improvement in the Physical function. Though a direct comparison with laminectomy was not done, the authors felt that the success rate observed in this study is comparable to the good outcome following laminectomy (55%-70%) in the existing literature. 39 -41 However, some of the concerns raised by the FDA (Food and Drug Administration) with this trial were as follows 42 : (1) the block randomization used could potentially be used to select patients more likely to respond to the device, (2) outcomes in both groups were significantly worse than expected, which calls into question the validity of the power calculations, and (3) results from 1 particular center were clearly superior to results from other centers. Four-year follow-up on 18 of the X-STOP patients showed that 78% of patients had a successful outcome by measurement using the ODI. 29 However, this study has significant shortcomings. Only 18 of the original 100 patients who had insertion of X-STOP were included. Also, in the 4-year results, the ODI scores were reported instead of ZCQ scores, as were documented in the pivotal study. The reason for this is unclear. This makes it very difficult to draw any definite conclusions from the 4-year study. It is worth mentioning here that the 2-year follow-up SF-36 data of 82 of the 100 X-STOP-treated patients and 53 of 91 nonoperatively treated patients were published separately. 28 The findings were as follows: (1) mean domain scores in X-STOP-treated patients were significantly greater than those in patients treated nonoperatively, with the exception of the mean General Health, Role Emotional, and Mental Component Summary scores at 2 years; and (2) mean post treatment domain scores documented in X-STOP-treated patients were significantly greater than mean pretreatment scores, with the exception of mean General Health scores at 6, 12, and 24 months.
The application of X-STOP in patients with Grade I spondylolisthesis was specifically studied in a prospective, comparative, multicenter, randomized trial in a cohort of 75 patients by Anderson et al, using SF-36 and ZCQ. 30 They reported clinical success of 63% in implant group compared to 13% in nonsurgical group. These results were, however, not replicated by Verhoof et al. In their cohort of 12 consecutive patients with symptomatic lumbar spinal stenosis caused by degenerative spondylolisthesis and treated with the X-STOP, there was a second need for surgery in 58% of the patients. The authors felt that any grade of degenerative spondylolisthesis be considered a contraindication for X-STOP placement. 26 Further trials are needed to look into the effect of X-STOP in patients with degenerative spondylolisthesis.
Other single center noncomparative studies on the effect of X-STOP in lumbar canal stenosis (Table 2) suggest varying degrees of satisfactory outcome. 12, 25, 27 In a recent publication on X-STOP, Barbagallo et al 22 looked into the complications of X-STOP. Of a total of 69 patients, 8 had complications. These included 4 device dislocations and 4 spinous process fractures. Of these 8, 7 patients (10.14%) required revision surgery. In another recent paper, Sobottke et al 23 did not find any significant correlation between radiologic parameters and clinical outcome. It is also worth noting that only 175 (17.5%) of a total of more than 1000 patients seen in their outpatients clinic with symptoms of intermittent claudication due to spinal stenosis were suitable for X-STOP insertion. 
Wallis Implant
Biomechanical Studies
The initial studies were limited to the titanium prototype. [43] [44] [45] The published biomechanical data on the second generation implant is scanty. In 2007, the developer along with coworkers published a combined in vitro and finite-element model analysis of the second generation implant. In vitro study results showed that the device placement after a simulated herniectomy and partial discectomy reduced the instrumented level range of movement to near intact levels. Finite-element model analysis indicated a decrease in disc stresses and increase in loads transmitted through the spinous processes. 46 Korovessis et al 20 conducted a prospective controlled study to see if Wallis implant reduces adjacent segment degeneration(ASD) above lumbosacral instrumented fusion. Their study concluded that Wallis interspinous implant changed the natural history of ASD and saved the 2 cephalad adjacent unfused vertebrae from fusion, while it lowered the radiographic ASD incidence until up to 5 years after surgery.
Clinical Evidence
Senegas et al has recently published his results of a 13-year mean follow-up of 107 patients. 37 All patients had initially been scheduled for decompression and fusion for canal stenosis, herniated disc, or both. In 20 patients, the implant had to be removed, and fusion was performed. The other 87 still had the dynamic stabilizer. Satisfaction, Oswestry disability index, visual analog scales for back and leg pain, short-form (SF-36) quality-of-life physical composite score, physical function, and social function were significantly better (P Յ 0.05) in the patients who still had the dynamic stabilization device. The study showed that the device provided a good 13-year clinical outcome and obviated arthrodesis in around 80% of the total 107 patients. However, this is a retrospective study with no control. It is, therefore, difficult to say whether the good results are due to the decompression alone or not.
Floman et al (2007) published a retrospective study evaluating the new implant. 36 The aim was to assess whether implant placement resulted in a subsequent lower incidence of recurrent disc herniation and further surgery. Thirty-seven patients underwent primary lumbar disc excision followed by fixation of the segment with the Wallis implant. After an average follow-up of 16 months, 13% of patients had recurrent herniations. This is in comparison to an independently published figure showing that 14% of primary lumbar discectomies require additional surgical intervention. 47 They concluded that the Wallis implant is probably incapable of reducing the incidence of recurrent herniations. They also attempted to evaluate the clinical benefits after implant placement. However, only 14 of the total 37 patients were evaluated for pain/disability scores. The average ODI and VAS dropped and SF-36 scores improved significantly in these 14 implanted patients. It is probably inappropriate to attribute these clinical gains to the implant alone as the concomitant decompressive surgery is likely to significantly contribute to the outcome.
Coflex
Biomechanical Studies Biomechanical studies on the coflex device shows the following effects on the kinematics of the spine: (1) significant reduction in flexion-extension range of motion at instrumented level; (2) stabilization of a partially destabilized cadaveric specimen to intact condition in terms of motion in flexion/extension and axial rotation; (3) no significant increase in range of motion at adjacent level when compared to PLIF (posterior lumbar interbody fusion) . [17] [18] [19] Trautwein et al 17 did a study to determine the in vivo posterior loading environment of the Coflex. The average loads exerted by the Coflex implant on the spinous process and lamina are 11.3% and 7.0% of their respective static failure load. As the implant fatigue strength is significantly higher than the measured median force, they concluded that Coflex fatigue failure is extremely rare.
Clinical Evidence
In a clinical study on Coflex by Kong et al, 19 18 patients undergoing Coflex placement and concomitant lumbar decompression were compared with 24 patients undergoing PLIF. 19 The study was retrospective and nonrandomized. All patients in the study had mild segmental instability. Clinical evaluation was done using VAS and ODI which improved significantly in both the patient groups. However, the range of motion at the upper adjacent segments (L3-L4) increased significantly after surgery in the PLIF group, which was not manifested in the Coflex group during the follow-up. The authors assumed that interspinous implantation can be an alternative treatment for the spinal stenosis with segmental instability in selected conditions posing less stress on the superior adjacent level than PLIF. In a recent prospective controlled study, Richter et al 35 evaluated the surgical outcome of decompressive surgery in comparison to decompressive surgery and additional implantation of the Coflex interspinous device in patients with lumbar spinal stenosis. A total of 60 patients were divided into 2 groups. Of them, 30 patients were treated with decompression surgery alone and in the other 30 patients a Coflex device was additionally implanted. At 1-year follow-up, there were no statistically differences between both groups in all ascertained parameters including patient satisfaction and subjective operation decision.
DIAM
Biomechanical Studies
Analysis of the biomechanical studies revealed the following: (1) decrease range of motion at instrumented level with no significant change at adjacent level, (2) decrease in intradiscal pressure at instrumented level, (3) no significant change in disc height or sagittal alignment, and (4) after discectomy, the angular motion was restored to below the level of the intact segment in flexionextension but failed to stabilize in rotation.
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Clinical Evidence
In one of the earliest clinical series, Mariottini et al implanted DIAM in 43 patients following nerve decompression. They reported "satisfying" results in 97% of cases. 33 In the series by Kim et al, there was statistically no difference in radiculopathy or low back pain VAS or McNab outcomes in patients with or without placement of implant after decompressive surgery. 15 A retrospective analysis of 104 patients operated as far back as 2001 were published in 2007 by Jean Taylor, the developer of the implant. 32 The implant was placed in a "wide variety of lumbar disorders." A retrospective evaluation was performed based on chart review and patient questionnaire. The questionnaire revealed that at 18 months after surgery, analgesic usage was decreased in 63.1%, increased in 12.3%, and unchanged in 24.6% of patients, and activities of daily living were improved in 46.2%, decreased in 30.8%, and unchanged in 23.1%. Specific outcomes measures for sitting, standing, physical activity, and psychosocial functioning revealed similar results.
Conclusion
There has been a deluge of ISPs currently available in the market. There have been several indications proposed by the developers as well. Current biomechanical evidence suggests a beneficial effect of interspinous devices on the kinematics of the degenerate spine. The trial by Zucherman et al 10 shows that X-STOP may be beneficial when compared to nonoperative treatment in select group of patients aged 50 years or over with radiologically confirmed lumbar canal stenosis whose symptoms improve on flexion. Despite the trial by Anderson et al, 30 the use of X-STOP in degenerative spondylolisthesis is controversial. Other studies on X-STOP and other devices have shown promising clinical results. But these studies are mostly retrospective and do not provide us with high level of evidence. Therefore, it is very difficult to reach a firm conclusion regarding the widespread use of spacers for all the proposed indication. There is also very little in the literature regarding long-term follow-up, including revisional surgery, complications and failure rate. Several randomized controlled trials are currently under way. The results of these trials are keenly awaited based on which the indications for insertion of ISPs may be revised.
Key Points
• Lumbar ISPs may be beneficial for a select group of patients. • However, prospective randomized controlled trials are lacking.
• Further good quality trials are needed to clearly outline the indications for their use.
